Paper34975752
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L and 13 others. Front Endocrinol (Lausanne), 2021. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. Papers, record 34975752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34975752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenoma | Major topic |
| Early Medical Intervention | Major topic |
| Pituitary Neoplasms | Major topic |
| Temozolomide | Major topic |
| Adult | |
| Cohort Studies | |
| Female | |
| Humans | |
| India | |
| Male | |
| Middle Aged | |
| Neoadjuvant Therapy | |
| Neoplasm Invasiveness | |
| Prognosis | |
| Retrospective Studies | |
| Treatment Outcome |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30031177 | Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. | World Neurosurg | 2018 | https://conductscience.org/library/papers/30031177 | PubMed |
| 2 | 30210447 | Imatinib Inhibits GH Secretion From Somatotropinomas. | Front Endocrinol (Lausanne) | 2018 | https://conductscience.org/library/papers/30210447 | PubMed |
| 3 | 26614517 | Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. | J Neurooncol | 2016 | https://conductscience.org/library/papers/26614517 | PubMed |
| 4 | 33285600 | Bevacizumab in Aggressive Pituitary Adenomas - Experience with 3 Patients. | Exp Clin Endocrinol Diabetes | 2021 | https://conductscience.org/library/papers/33285600 | PubMed |
| 5 | 31311005 | How and when to use temozolomide to treat aggressive pituitary tumours. | Endocr Relat Cancer | 2019 | https://conductscience.org/library/papers/31311005 | PubMed |
| 6 | 31746334 | Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. | J Clin Endocrinol Metab | 2020 | https://conductscience.org/library/papers/31746334 | PubMed |
| 7 | 31349217 | Treatment and long-term outcomes in pituitary carcinoma: a cohort study. | Eur J Endocrinol | 2019 | https://conductscience.org/library/papers/31349217 | PubMed |
| 8 | 31808044 | Definition and diagnosis of aggressive pituitary tumors. | Rev Endocr Metab Disord | 2020 | https://conductscience.org/library/papers/31808044 | PubMed |
| 9 | 20660056 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. | J Clin Endocrinol Metab | 2010 | https://conductscience.org/library/papers/20660056 | PubMed |
| 10 | 33089448 | Differential independent impact of the intraoperative use of navigation and angled endoscopes on the surgical outcome of endonasal endoscopy for pituitary tumors: a prospective study. | Neurosurg Rev | 2021 | https://conductscience.org/library/papers/33089448 | PubMed |
| 11 | 34295309 | Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34295309 | PubMed |
| 12 | 30610566 | The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas. | Endocr Pathol | 2019 | https://conductscience.org/library/papers/30610566 | PubMed |
| 13 | 32415572 | Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature. | J Endocrinol Invest | 2020 | https://conductscience.org/library/papers/32415572 | PubMed |
| 14 | 25027022 | The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. | J Exp Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25027022 | PubMed |
| 15 | 28432119 | Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. | Eur J Endocrinol | 2017 | https://conductscience.org/library/papers/28432119 | PubMed |
| 16 | 30306782 | Aggressive and malignant pituitary tumours: state-of-the-art | Endocr Relat Cancer | 2018 | https://conductscience.org/library/papers/30306782 | PubMed |
| 17 | 29381964 | Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/29381964 | PubMed |
| 18 | 23400299 | A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. | Acta Neuropathol | 2013 | https://conductscience.org/library/papers/23400299 | PubMed |
| 19 | 31267325 | Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. | Endocrine | 2019 | https://conductscience.org/library/papers/31267325 | PubMed |
| 20 | 16750503 | Temozolomide: a novel treatment for pituitary carcinoma. | Lancet Oncol | 2006 | https://conductscience.org/library/papers/16750503 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42573676 | Determinant factors for headache at acromegaly diagnosis: findings from an Iberian multicenter study encompassing 726 patients. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/42573676 | PubMed |
| 42557589 | Can acromegaly be controlled in all cases? | J Neuroendocrinol | 2026 | https://conductscience.org/library/papers/42557589 | PubMed |
| 41894067 | Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study. | Pituitary | 2026 | https://conductscience.org/library/papers/41894067 | PubMed |
| 40806825 | Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas. | J Clin Med | 2025 | https://conductscience.org/library/papers/40806825 | PubMed |
| 39736867 | Everolimus in pituitary tumor: a review of preclinical and clinical evidence. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/39736867 | PubMed |
| 39224564 | Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors. | Int J Endocrinol | 2024 | https://conductscience.org/library/papers/39224564 | PubMed |
| 38760632 | Medical treatment of functional pituitary adenomas, trials and tribulations. | J Neurooncol | 2024 | https://conductscience.org/library/papers/38760632 | PubMed |
| 38738958 | The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment. | CNS Neurosci Ther | 2024 | https://conductscience.org/library/papers/38738958 | PubMed |
| 38370355 | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38370355 | PubMed |
| 38202123 | Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use. | J Clin Med | 2023 | https://conductscience.org/library/papers/38202123 | PubMed |
| 37871278 | Epigenome-wide association study of systemic effects of obesity susceptibility in human twins. | Epigenetics | 2023 | https://conductscience.org/library/papers/37871278 | PubMed |
| 37720528 | Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37720528 | PubMed |
| 35059545 | Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. | J Endocr Soc | 2022 | https://conductscience.org/library/papers/35059545 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34975752
GET https://conductscience.org/api/papers/v1/34975752/references?page=2